Pipeline

Pulmonology
Esbriet® (pirfenidone) - Idiopathic Pulmonary Fibrosis
European Union and Canada
United States
PANORAMA Study (Esbriet +/- NAC)
Pirfenidone Formulations
Pirfenidone – Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)
LOTUSS Study (SSc-ILD)
Specialty Fibrotic Diseases
Pirfenidone Analog
LPA-I Inhibitor
Drug Discovery Programs

You are now leaving the InterMune website. If you would like to continue, click Continue. Otherwise, click Cancel.
CancelContinue